Here’s what you need to know:
1. Portaban is an oral drug made with ifetroban, which was shown to reduce portal pressure, necrosis, inflammation and fibrosis in liver injury during preclinical studies.
2. The researchers will study whether Portaban can lower elevated portal pressures in patients with portal hypertension, a complication of liver cyrossis.
3. The researchers believe the drug will decrease risk of hepatic decompensation and may even improve long-term liver function.
4. Portaban is Cumberland Pharmaceuticals’ fourth development candidate. Its other products include treatments for hepatorenal syndrome, respiratory disease and systemic sclerosis.
More articles on gastroenterology and endoscopy:
Hepatitis C-infected organs may prove safe transplants: 4 study insights
Endoscopic suturing effectively closes colonoscopy perforations: 5 study insights
Mount Sinai Hospital adopts Cellvizio System: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.